37 results about "Streptococcal disease" patented technology

The invention provides an SNP (Single Nucleotide Polymorphism) site combination for identifying streptococcicosis resistance of tilapia and application of the SNP site combination. DNAs of tilapia tail fin tissues attacked by streptococcus agalactiae are re-sequenced, resistant and sensitive individuals of a tilapia population are screened, GWAS analysis is carried out, SNPs sites related to tilapia streptococcus agalactiae disease resistance are identified, functional gene annotation and enrichment analysis are carried out, two SNP sites LG1320881657 and LG1320548718 are screened, and the SNP sites related to tilapia streptococcus agalactiae disease resistance are obtained. The GG genotype of the LG1320881657 and the TT genotype of the LG1320548718 are the dominant genotypes related to the streptococcus agalactiae disease resistance of the tilapia mossambica. The tilapia mossambica resistant to streptococcosis is successfully screened by utilizing the two SNPs sites, effective SNPs are provided for developing tilapia mossambica anti-streptococcosis molecular marker-assisted breeding, excellent characters of parents are ensured, and the breeding efficiency is improved.

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

The invention discloses an application of marine streptomyces SH110 and a source compound thereof, the marine streptomyces SH110 has a preservation number of GDMCC (China General Microbiological Culture Collection Center) NO.66668, and the preservation date is July 14, 2025; the invention also discloses application of the marine streptomyces SH110-derived compound in preparation of a medicine for preventing and treating streptococcus and vibrio diseases. The marine streptomyces source compound has efficient vibrio and streptococcus resisting activity, the vibrio and streptococcus resisting activity is not reported, and the marine streptomyces source compound has new application. The marine streptomyces source compound is used for preparing the medicine for preventing and treating the vibrio and streptococcus diseases, especially for preparing the medicine for preventing and treating the vibrio and streptococcus diseases of aquaculture animals, the safety is high, and the treatment effect is good.

The invention relates to the technical field of biology, in particular to a tilapia mossambica streptococcus agalactiae resistance related KASP molecular marker and application thereof. According to the invention, two SNP (Single Nucleotide Polymorphism) loci, namely SNP-1 and SNP-2, which are remarkably associated with resistance are screened based on an intron region of an EGFRX2 gene of tilapia mossambica, a typing method of the loci is developed through a KASP technology, and relevance between the genotype of the SNP-1 and a resistance phenotype is verified. Furthermore, streptococcus agalactiae resistance dominant diplotype individuals are screened in combination with double SNP loci, and the survival rate of a challenge experiment is remarkably improved. The detection kit provided by the invention can realize high-throughput and high-precision typing, is suitable for tilapia mossambica resistance genotype identification and molecular marker-assisted breeding, provides an efficient genetic improvement tool for tilapia mossambica disease-resistant breeding, and is beneficial to reduction of breeding disease loss and reduction of antibiotic dependence.

The invention provides a streptococcus suis polysaccharide protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The vaccine comprises a polysaccharide-protein conjugate formed by coupling streptococcus suis type 2 capsular polysaccharide and streptococcus suis type 2 recombinant protein. The preparation method comprises the following steps: S1, preparing streptococcus suis type 2 capsular polysaccharide; s2, preparing streptococcus suis type 2 recombinant protein; s3, activating polysaccharide; s4, combining the biotinylated polysaccharide with the recombinant protein containing the avidin structural domain to form a stable polysaccharide-protein conjugate; s5, removing unbound proteins; and S6, mixing the polysaccharide-protein conjugate with the oil-water emulsion in proportion. By optimizing a coupling technology and a vaccine preparation formula, the immunogenicity and the protection effect of the vaccine are improved, the safety and the broad-spectrum cross protection capability of the vaccine are remarkably enhanced, the complexity and the cost of a vaccine production process are reduced, and the vaccine has a good industrial application prospect and a good popularization value.

The invention discloses a kit and a method for rapidly detecting streptococcus suis and Graisseria parasuis based on a dual LAMP-LFD (loop-mediated isothermal amplification-lateral flow dipstick) technology, and belongs to the field of molecular biological detection. According to the method, a double LAMP primer combination is used for amplifying a gdh gene of streptococcus suis and an infB gene of Graisseria parasuis, and rapid detection is carried out by combining a transverse flow test strip. The kit comprises a dual LAMP primer combination (SEQ ID No.1-SEQ ID No.8), and an LAMP reaction premix solution, a Bst II DNA polymerase, positive and negative controls, an amplification product diluent (ddH2O) and a transverse flow test strip which can be added according to requirements, and can also comprise internal standard DNA, a genome DNA degrading enzyme and specially designed nanoparticles. By means of the automatic temperature control device, the method can complete the whole process from sample treatment to result judgment within 45 minutes, and is suitable for on-site rapid detection. The invention provides an efficient, simple and convenient detection scheme, rapid diagnosis of the swine streptococcosis and the glaisseria parasuis can be achieved, and effective technical support is provided for prevention and control work of the swine streptococcosis and the glaisseria parasuis.

The invention relates to an SNP site associated with trachinotus ovatus and streptococcus iniae disease resistance characters and application, and belongs to the technical field of molecular biological breeding, the SNP site is located at the 14078454 site on the No.7 chromosome, the polymorphism site is C / T, and the genotype of the site with disease resistance is CC. The invention also provides application of the SNP site in identification of streptococcus iniae resistant trachinotus ovatus, and the application method comprises the following steps: extracting DNA (deoxyribonucleic acid) of the trachinotus ovatus to be identified, and selecting individuals with CC genotype at the SNP site through sequencing. And screening the genotype of which the SNP site is CC as a breeding parent. The method is used for cultivating a new trachinotus ovatus variety resistant to streptococcus iniae.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention relates to a traditional Chinese medicine compound for preventing and treating fish streptococcicosis, and belongs to the technical field of research and development of aquaculture disease prevention and control medicines and feed additives. The traditional Chinese medicine compound for preventing and treating fish streptococcicosis comprises the following effective components: coptis chinensis, ginger and Chinese dates, the mass ratio of the coptis chinensis to the ginger to the Chinese dates is (12.0-16.0): (2.0-4.0): (7.4-9.2). The formula is safe and non-toxic to fish, has a good prevention and treatment effect on fish streptococcosis, and is environment-friendly, wide in raw material source, low in price, good in biocompatibility and simple in preparation process.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

The invention belongs to the research field of streptococcus agalactiae resistance of tilapia gill flora, and discloses a method for determining streptococcus agalactiae resistance of tilapia gill flora. According to the method, the Guifil No.1 growing quickly and the ZL resisting streptococcus agalactiae disease are subjected to reciprocal cross, and the streptococcus agalactiae resistance, catalase level and difference between a gill flora and a parent of a hybrid offspring are compared, so that the relationship between genetic differentiation and a gill flora structure is evaluated; the key function of tilapia gill flora in resisting streptococcus agalactiae is preliminarily revealed. Researches show that after the disease-resistant variety ZL is hybridized with the GIFT growing quickly, the filial generation of the disease-resistant variety ZL tends to inherit the flora of the ZL, and certain disease resistance is obtained.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention relates to the technical field of new application of a natural orange peel extract, in particular to a bacteriostatic agent of the natural orange peel extract and application of the bacteriostatic agent. Bacteriostatic experiments find that the natural extract hesperetin and / or hesperidin of the orange peel has a good bacteriostatic effect on most of aquaculture indicator bacteria. Animal experiments after the hesperetin and / or hesperidin are prepared into the disease-resistant feed find that the hesperetin or hesperidin can effectively improve the resistance of fishes to streptococcus iniae infection. A 5 * MIC hesperetin group shows the best protection effect, the protection rate reaches 60%, and the protection rate of streptococcus iniae fed with a hesperidin group is 46%. Therefore, the hesperetin and / or the hesperidin which is the natural extract of the orange peel can be used as a bacteriostatic agent or a bacteriostatic feed in aquaculture, new application of the hesperetin and the hesperidin in aquaculture is developed, and the hesperetin and the hesperidin have important significance in controlling and preventing streptococcicosis.

The invention discloses an unsaturated fatty acid compound derived from coral symbiotic streptomyces and an application of the unsaturated fatty acid compound. The chemical structural formula of the sisa coral acid A is as shown in formula (I). The invention further discloses application of the unsaturated fatty acid compound derived from the coral symbiotic streptomyces in preparation of a medicine for preventing and treating streptococcus diseases. The cisacolinic acid A provided by the invention is derived from natural organisms, and has low side effects and excellent activity. The sisaxacoral acid A can be produced by fermenting marine streptomyces sp.SHEa3, fermentation raw materials are easy to obtain, the production process is green and environment-friendly, the cost is low, and the sisaxacoral acid A has excellent anti-streptococcus activity and is suitable for being used for preparing a medicine for preventing and treating streptococcus diseases.

The application discloses a SNP molecular marker related to the resistance of yellowfin snapper to streptococcus iniae disease, which is characterized by being located at the 10398424th base of the 5th chromosome of the yellowfin snapper; the sequence of the SNP molecular marker is shown as SEQ ID NO:1, and the 251th base from the 5' end is G or A; the resistance of the individual with the GG or GA genotype to the streptococcus iniae disease is higher than that of the individual with the AA genotype. The application further discloses primers, a kit for detecting the SNP molecular marker, a method for breeding the yellowfin snapper with the resistance to the streptococcus iniae disease, and the application of the above-mentioned primers, the kit and the method in breeding the yellowfin snapper with the resistance to the streptococcus iniae disease.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

[Problem] To isolate and identify novel Lactococcus gasseri, and to provide an effective means for preventing diseases in which said Lactococcus gasseri is used as a pathogenic bacterium. [Solution] Provided is an inactivated vaccine preparation and the like against fish streptococcosis that uses Lactococcus gasseri as a pathogenic bacterium, said inactivated vaccine preparation containing inactivated cells of Lactococcus gasseri that are negative in agglutination against type I serum and type II serum in a viable state. It is possible to effectively prevent the occurrence, propagation, and propagation of novel streptococcosis that cannot be prevented by conventional inactivated vaccines against Lactococcus gasseri.

The invention discloses an SNP (Single Nucleotide Polymorphism) molecular marker related to streptococcus iniae disease resistance of sparus latus, which is characterized in that the SNP molecular marker is positioned at a 10398424-site basic group of a fifth chromosome of sparus latus; the sequence of the SNP molecular marker is as shown in SEQ ID NO: 1, and the basic group of the 251st site from the 5'end is G or A; wherein the streptococcus iniae disease resistance of a GG or GA genotype individual is higher than that of an AA genotype individual. The invention also discloses a primer and a kit for detecting the SNP molecular marker, and a method for breeding the sparus latus with streptococcus iniae disease resistance. The invention further discloses application of the primer, the kit and the method in breeding the streptococcus iniae disease resistant sparus latus.

The present invention relates to a method for synthesizing rhamnose polysaccharide. The present invention also relates to streptococcal polysaccharides, streptococcal glycoconjugates, immunogenic compositions or vaccines comprising streptococcal polysaccharides or glycoconjugates, and polysaccharides, glycoconjugates, immunogenic compositions or vaccines for enhancing the immune response of animals or for treating or preventing diseases, disorders or infections caused by streptococcal etiology.

The present disclosure relates to a technique for stably storing an inactivated vaccine against type II streptococcosis in fish. The present disclosure relates to, for example, a lyophilizate of an inactivated vaccine against type II streptococcosis in fish, the lyophilizate comprising: inactivated cells of a causative bacterium of type II streptococcosis; and a cryoprotectant. The present disclosure relates to, for example, a method for storing an inactivated vaccine against type II streptococcosis in fish, the method comprising refrigerating the inactivated vaccine at 10°C or lower, the inactivated vaccine comprising inactivated cells of a causative bacterium of type II streptococcosis, and being in a lyophilized form.

The present invention relates to the development of a microencapsulated vaccine containing inactivated Streptococcus agalactiae, together with the adjuvants beta glucan and mineral oil, to be administered orally to fish together with feed in pelletised form or coated with the vaccine. In addition, the invention relates to the use of this vaccine to immunise fish, more specifically Nile tilapia (Oreochromis niloticus) to activate both innate and adaptive (humoral and cellular) intestinal mucosal immunity and protect tilapia against streptococcosis. Such a vaccine can be applied in intensive fishing production systems, with the aim of reducing fish mortality, reducing the use of antimicrobials and not causing environmental damage, being easy to administer and control, reducing fish handling, and being suitable for immunising large numbers of animals at the same time without stress and at low cost.

The invention belongs to the technical field of gene engineering, and particularly relates to streptococcus agalactiae Mu-20 and a construction method and application thereof. The fish-derived streptococcus agalactiae which is lack of capsular polysaccharide, free of hyaluronidase activity, free of hemolysis and negative in trehalose fermentation is constructed, the strain number is Mu-20, the fish-derived streptococcus agalactiae is preserved in Guangdong Microbial Culture Collection Center on June 13, 2022, and the preservation number is GDMCC No: 62540; the strain does not carry chloramphenicol resistance marker genes, is high in biological safety, has no risk of virulence enhancement, is high in immunogenicity, and can protect immunized fish from resisting invasion of streptococcus agalactiae, and meanwhile, the attenuated live vaccine is easy to culture, simple to use and low in production cost; the strain provided by the invention can be used for preparing attenuated live vaccines for fish streptococcosis, and has extremely high commercial application value.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition which comprises glucocorticoid and penicillin. Aiming at the problems of poor treatment effect, poor prognosis and the like of clinically treating swine streptococcal meningitis at present, penicillin and glucocorticoid are combined, and meanwhile, the invention discloses a drug combination method. Microscopic examination, change of partial bacteria loading amount, blood brain barrier staining observation and the like are carried out to find that the composition can effectively treat streptococcus suis infection and can quickly reduce brain inflammation, so that the blood brain barrier damaged by streptococcus suis is repaired, and the effect is better than that of a single component; therefore, the prognosis effect of streptococcal meningitis of swine can be improved to the greatest extent. Meanwhile, the composition is a common medicine, and a new feasible thought is provided for clinically treating the streptococcus suis diseases.

The invention relates to the technical field of feed additives, in particular to a traditional Chinese medicine composition for preventing and treating streptococcus iniae diseases of humpback perches as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-15 parts of eucommia ulmoides, 10-15 parts of folium artemisiae argyi, 10 parts of radix angelicae, 10-13 parts of rhizoma zingiberis, 10-12 parts of liquorice, 7-9 parts of caulis spatholobi, 7-8 parts of herba ecliptae, 7-8 parts of radix ophiopogonis, 6-7 parts of poria cocos, 7-8 parts of hawthorn, 3-5 parts of radix aucklandiae, 3-4 parts of dendrobe, 3-5 parts of radix pulsatillae and 3-5 parts of radix puerariae. By feeding the traditional Chinese medicine composition provided by the invention, the weight gain rate of the humpback perches is increased by 20%, and the death rate of the humpback perches infected with streptococcus iniae is reduced by 10%.

There is currently a high demand for new therapeutic antibiotics with new mechanisms of action. Disclosed are two small molecules, tryglysin A and B, with novel chemical structures and potent antibiotic activity against a narrow spectrum of bacteria. This narrow spectrum of activity indicates the tryglysins could be working through a novel antibiotic mechanism of action. Due to this narrow spectrum, the tryglysins could be used as highly targeted therapeutics to treat or prevent disease without disturbing other important, “beneficial” bacteria within the human microbiome, which is a great improvement over virtually all other clinically used antibiotics that are broad-spectrum. The tryglysins are potent against several streptococcal pathogens, including Streptococcus pneumonia, the leading cause of pneumonia, and Streptococcus mutans, the primary causative agent of tooth decay and gum disease. The tryglycins may allow the development of therapeutics for the treatment and / or prevention of disease caused by these streptococci.

The present invention provides a dual fluorescent quantitative PCR kit for simultaneously detecting Streptococcus pasteurianus and Streptococcus suis, belonging to the field of bacterial detection. The kit includes a primer pair and a probe. The primer pair and probe for Streptococcus pasteurianus include SP-3230F, SP-3230R and SP-probe, and the nucleotide sequence is shown in SEQ ID NO: 1-3; the primer pair and probe for Streptococcus suis include SS-recNF, SS-recNR and SS-probe, and the nucleotide sequence is shown in SEQ ID NO: 4-6. The kit of the present invention has the advantages of high sensitivity, high specificity, low pollution and real-time detection, and provides reliable technology and products for the early diagnosis, monitoring, early warning and prevention of clinical streptococcal disease in pigs in farms.

The present application relates to the field of biotechnology, and particularly relates to SNP marker combination for identifying resistance to streptococcus agalactiae disease of tilapia and application thereof. The present application discloses 11 SNP sites in UTRN gene of tilapia which are significantly related to resistance to streptococcus agalactiae disease, and constructs 18 SNP marker combinations for identifying resistance phenotype of streptococcus agalactiae disease, which can effectively improve the accuracy and genetic stability of resistance phenotype identification. In addition, the SNP typing primer and method based on MALDI-TOF mass spectrometry platform provided by the present application can realize high-throughput and high-precision genotyping, and has important application value in resistance phenotype identification and assisted selection breeding.

The invention belongs to the field of livestock breeding or medicine, and particularly relates to application of a cinnamon leaf extract in the aspect of preventing and treating human-livestock diseases, fish streptococcus agalactiae diseases or dairy cow mastitis caused by streptococcus agalactiae. The cinnamon leaf extract has good bacteriostatic and bactericidal effects on streptococcus agalactiae and streptococcus iniae. Besides, the cinnamon leaf extract is strong in fragrance, green, environment-friendly, free of solvent residues and high in palatability, can be added into feed, has the effects of aroma enhancement and antibiosis, effectively reduces the use of antibiotics in fish breeding and dairy cow breeding processes, and is also beneficial to improving the food safety. In daily nursing prevention and treatment, the cinnamon leaf extract can also be used as an oil-soluble raw material to be used as an antibacterial agent for various florae such as streptococcus agalactiae so as to reduce the application of preservatives.

The invention discloses a composite bacteriostatic agent for preventing and controlling streptococcicosis of tilapia mossambica as well as a preparation method and application thereof. The compound bacteriostatic agent is prepared from 25 percent to 30 percent of gallnut tannin nano microcapsules, 25 percent to 35 percent of eucommia ulmoides chlorogenic acid-chitosan compound, 10 percent to 20 percent of baicalin phospholipid compound, 5 percent to 15 percent of bacillus subtilis GS-02 metabolite freeze-dried powder and the balance of acidified modified attapulgite. By adding 1.5% of the compound bacteriostatic agent into feed, the accumulative incidence rate of streptococcicosis can be remarkably reduced to 5.3%, the weight gain rate is increased by 22.1%, the feed coefficient is reduced to 1.21, and no enrofloxacin drug residue exists. The compound bacteriostatic agent is suitable for various application scenes such as feed addition, water splashing and slow-release gels; the sustained-release gel block is especially suitable for a recirculating aquaculture system, and can maintain an effective antibacterial concentration for 30 days when being suspended in a sustained-release gel block form according to 200g per 10m < 3 > of water body, so that the accumulated infection rate of streptococcus is reduced to be less than or equal to 1.2%.